RECCE PHARMACEUTICALS LTD |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.66 AUD | 0.00% |
|
+1.54% | +23.36% |
| Apr. 17 | Recce Pharmaceuticals Ltd. Completes 5,000 RECCE 327 Doses Week Under Good Manufacturing Practice | CI |
| Apr. 16 | Recce Pharmaceuticals Advances Production of Anti-Infective Medication | MT |
Valuation
| Fiscal Period: Juni | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 158.1 | 111.4 | 134.6 | - | - |
| Enterprise Value (EV) 1 | 158.1 | 113 | 139 | 143.9 | 130.7 |
| P/E ratio | -14.1 x | -8.31 x | -8.25 x | -3.99 x | -15.7 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | 25.8 x | 25.7 x | 23.6 x | 43.4 x |
| EV / Revenue | - | 26.2 x | 26.6 x | 25.3 x | 42.2 x |
| EV / EBITDA | - | -8.83 x | -9.39 x | -4.73 x | -13.6 x |
| EV / FCF | - | -8.88 x | -9.4 x | -4.32 x | -13.6 x |
| FCF Yield | - | -11.3% | -10.6% | -23.1% | -7.34% |
| Price to Book | - | - | - | - | - |
| Nbr of stocks (in thousands) | 177,647 | 178,254 | 203,952 | - | - |
| Reference price 2 | 0.8900 | 0.6250 | 0.6600 | 0.6600 | 0.6600 |
| Announcement Date | 8/31/22 | 8/31/23 | - | - | - |
1AUD in Million2AUD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: Juni | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | 4.311 | 5.236 | 5.696 | 3.1 |
| EBITDA 1 | - | -12.8 | -14.8 | -30.42 | -9.6 |
| EBIT 1 | - | -12.69 | -15.04 | -30.61 | -9.6 |
| Operating Margin | - | -294.33% | -287.32% | -537.42% | -309.68% |
| Earnings before Tax (EBT) 1 | - | -13.08 | -15.28 | -33.42 | -9.6 |
| Net income 1 | -10.99 | -13.08 | -15.28 | -33.42 | -9.6 |
| Net margin | - | -303.34% | -291.82% | -586.75% | -309.68% |
| EPS 2 | -0.0631 | -0.0752 | -0.0800 | -0.1655 | -0.0420 |
| Free Cash Flow 1 | - | -12.73 | -14.79 | -33.3 | -9.6 |
| FCF margin | - | -295.18% | -282.55% | -584.63% | -309.68% |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 8/31/22 | 8/31/23 | - | - | - |
1AUD in Million2AUD
Estimates
Balance Sheet Analysis
| Fiscal Period: June | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt 1 | - | 1.56 | 4.43 | 9.31 | - |
| Net Cash position 1 | - | - | - | - | 3.9 |
| Leverage (Debt/EBITDA) | - | -0.122 x | -0.299 x | -0.306 x | - |
| Free Cash Flow 1 | - | -12.7 | -14.8 | -33.3 | -9.6 |
| ROE (net income / shareholders' equity) | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets 1 | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - |
| Cash Flow per Share 2 | - | - | -0.0700 | -0.0400 | -0.0400 |
| Capex 1 | - | 0.04 | 0.13 | 0.14 | - |
| Capex / Sales | - | 0.9% | 2.44% | 2.46% | - |
| Announcement Date | 8/31/22 | 8/31/23 | - | - | - |
1AUD in Million2AUD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +23.36% | 87.41M | |
| +34.00% | 704B | |
| +27.09% | 577B | |
| -7.75% | 348B | |
| +18.53% | 327B | |
| +4.95% | 288B | |
| +14.91% | 234B | |
| +4.93% | 198B | |
| -9.78% | 194B | |
| -4.89% | 147B |
- Stock Market
- Equities
- RCE Stock
- Financials Recce Pharmaceuticals Ltd
